China Deal Monitor: Clover Biopharma raises $43m Series B and more updates

China Deal Monitor: Clover Biopharma raises $43m Series B and more updates

Clover Biopharmaceuticals, a clinical-stage biotechnology firm, has gathered 304 million yuan ($43 million) in its Series B round of financing led by Delos Capital and Lapam Capital, per a company statement. 

The fresh round also saw the participation of Betta Capital, Sichuan Health Care Industry Fund, Beijing Zhongguancun VC and Jinlong Group. BFC Group served as a financial advisor on the deal.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter